Government-Owned Inventions; Availability for Licensing, 75177-75179 [2010-30279]
Download as PDF
<![CDATA[
WReier-Aviles on DSKGBLS3C1PROD with NOTICES
Federal Register / Vol. 75, No. 231 / Thursday, December 2, 2010 / Notices
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Gastrointestinal
Drugs Advisory Committee.
General Function of the Committee:
To provide advice and
recommendations to the Agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on January 12, 2011, from 8 a.m to
5 p.m.
Location: FDA White Oak Campus,
10903 New Hampshire Ave., Silver
Spring, MD 20993–0002, Bldg. 31, the
Great Room, White Oak Conference
Center (rm. 1503). Information regarding
special accommodations due to a
disability, visitor parking and
transportation may be accessed at:
https://www.fda.gov/
AdvisoryCommittees/default.htm; under
the heading ‘‘Resources for You,’’ click
on ‘‘White Oak Conference Center
Parking and Transportation Information
for FDA Advisory Committee Meetings.’’
Please note that visitors to the White
Oak Campus must have a valid driver’s
license or other picture ID, and must
enter through Building 1.
Contact Person: Kristine T. Khuc,
Center for Drug Evaluation and
Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 31, rm. 2417, Silver Spring,
MD 20993–0002, 301–796–9001, FAX:
301–847–8533, e-mail:
kristine.khuc@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area), code
3014512538. Please call the Information
Line for up-to-date information on this
meeting. A notice in the Federal
Register about last minute modifications
that impact a previously announced
advisory committee meeting cannot
always be published quickly enough to
provide timely notice. Therefore, you
should always check the Agency’s Web
site and call the appropriate advisory
committee hot line/phone line to learn
about possible modifications before
coming to the meeting.
Agenda: On January 12, 2011, the
committee will discuss the safety and
efficacy of new drug application (NDA)
022–486, for Solpura (liprotamase)
Capsules, by Alnara Pharmaceuticals,
for the proposed indication (use) in the
treatment of exocrine pancreatic
insufficiency due to cystic fibrosis,
chronic pancreatitis, pancreatectomy
(surgical removal of all or part of the
pancreas), or other conditions that may
impair or limit function of the pancreas.
The pancreas is an organ involved, in
part, in the digestion of food through the
use of specialized proteins called
VerDate Mar<15>2010
15:28 Dec 01, 2010
Jkt 223001
enzymes. Exocrine pancreatic
insufficiency is a decreased ability to
digest food due to deficient enzyme
production by the pancreas.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before December 28, 2010.
Oral presentations from the public will
be scheduled between approximately 1
p.m. to 2 p.m. Those individuals
interested in making formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before
December 17, 2010. Time allotted for
each presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by December 20, 2010.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Kristine T.
Khuc at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
PO 00000
Frm 00009
Fmt 4703
Sfmt 4703
75177
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: November 26, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010–30274 Filed 12–1–10; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
Federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
SUMMARY:
Novel Compositions and Methods To
Treat Glioblastoma and Other Cancers
Description of Technology: There
remains a significant unmet need for
therapeutics to treating glioblastoma
multiforme, a very aggressive type of
brain tumor. Glioblastoma is difficult to
treat with conventional surgery,
chemical, and radiation therapies. With
approximately 18,000 new glioblastoma
cases in the U.S. each year, and a
comparable market in Europe, the global
market for such products forecast to be
over $300 million. In light of the high
unmet need in malignant astrocytoma
and little in the way of pipeline
competition, this indication represents a
potential easy route to market for new
drugs.
E:\FR\FM\02DEN1.SGM
02DEN1
75178
Federal Register / Vol. 75, No. 231 / Thursday, December 2, 2010 / Notices
Researchers at the National Cancer
Institute (NCI) have identified two novel
molecular targets, annexin 1 (Anx A1)
and its receptor formyl peptide receptor
1 (FPR1), for new anti-glioblastoma
therapies. Anx A1 and FPR1 mediate
growth, invasion, production of
angiogenic factors, tumor formation, and
are abnormally expressed by more
highly malignant glioblastomas.
Depletion of Anx A1 in glioblastoma
cells resulted in their reduced capacity
to form tumors; additional depletion of
FPR1 further reduced this capacity.
Further, the NCI researchers have found
a correlation between Anx A1
expression and the degree of
malignancy of human gliomas.
Novel anti-glioblastoma therapies
encompassed by this invention include
neutralizing antibodies against Anx A1
and FPR1, small compound agonists of
Anx A1 and FPR1, small interference
RNAs (siRNAs) that deplete Anx A1 and
FPR1 from glioblastoma cells, as well as
delivery methods to effectively
administer the Anx A1 and FPR1
targeting drugs into brain tissues.
Applications
• Treatment of glioblastoma
multiforme and other brain tumors.
• Treatments for inhibiting neoplastic
cell growth.
• Treatments for inhibiting tumor
progression and metastasis.
• Treatments for inhibiting
angiogenesis in a tumor.
WReier-Aviles on DSKGBLS3C1PROD with NOTICES
Advantages
• High specificity.
• Does not require radiation.
• A correlation between expression of
the molecular target and the degree of
tumor malignancy is known.
• Wide-range/flexibility of potential
therapies and approaches.
Development Status: Pre-clinical.
Inventors: Ji Ming Wang et al. (NCI).
Relevant Publication: Y Zhou, et al.
Formylpeptide receptor FPR and the
rapid growth of malignant human
gliomas. J Natl Cancer Inst. 2005 Jun
1;97(11):823–835. [PubMed: 15928303]
Patent Status: U.S. Provisional
Application No. 61/388,983, filed 01
Oct 2010 (HHS Reference No. E–297–
2010/0–US–01).
Licensing Status: Available for
licensing.
Licensing Contact: Patrick P. McCue,
Ph.D.; 301–435–5560;
mccuepat@mail.nih.gov.
Collaborative Research Opportunity:
The Center for Cancer Research,
Laboratory of Molecular
Immunoregulation, is seeking
statements of capability or interest from
parties interested in collaborative
VerDate Mar<15>2010
15:28 Dec 01, 2010
Jkt 223001
research to further develop, evaluate, or
commercialize this technology. Please
contact John Hewes, Ph.D. at 301–435–
3121 or hewesj@mail.nih.gov for more
information.
Synovial Sarcoma X Breakpoint-2
(SSX–2) Specific Human T Cell
Receptors for Treating a Wide-Range of
Cancers
Description of Technology: Many
current approaches for treating cancer
also generate harsh side effects in
patients. In addition, a sizable patient
population does not respond to
generalized chemotherapy and radiation
treatments for cancer. There is an urgent
need to develop new therapeutic
strategies aimed at reducing side-effects
and increasing specific anti-tumor
activity in individual patients. Adoptive
immunotherapy is a promising new
approach to cancer treatment that
engineers an individual’s innate and
adaptive immune system to fight against
specific diseases, including cancer. As
research and development continues in
this area, scientists continue to improve
cell transfer therapies by targeting an
increasing collection of tumor antigens
with more effective immune cell
cultures.
T cell receptors (TCRs) are proteins
that recognize antigens in the context of
infected or transformed cells and
activate T cells to mediate an immune
response and destroy abnormal cells.
TCRs consist of two domains, one
variable domain that recognizes the
antigen and one constant region that
helps the TCR anchor to the membrane
and transmit recognition signals by
interacting with other proteins. When a
TCR is stimulated by an antigen, such
as a tumor antigen, some signaling
pathways activated in the cell lead to
the production of cytokines, which
mediate the immune response.
Scientists at the National Institutes of
Health (NIH) have developed T cells
genetically engineered to recognize
synovial sarcoma X breakpoint-2 (SSX–
2) peptide antigens. SSX proteins,
including SSX–2, are expressed
primarily by tumor cells from a variety
of cancers, including pancreatic cancer
where very few treatment options exist.
Other than germ cells of the testis,
normal cells do not express SSX
proteins and, thus, should not be
targeted by therapies directed against
these proteins. Therefore, SSX proteins
represent a promising target for cancer
immunotherapy. There are ten (10)
known members of the SSX protein
family designated SSX–1 through SSX–
10. The T cell receptors (TCRs)
developed by these NIH scientists have
specificity for SSX–2 and deliver a
PO 00000
Frm 00010
Fmt 4703
Sfmt 4703
robust immune response when they
encounter SSX–2 expressing cells.
However, these TCRs also recognize five
(5) other SSX family members,
including SSX–3, SSX–4, SSX–5, SSX–
9, and/or SSX–10, and deliver a
productive, intermediate immune
response in the context of target cells
expressing these antigens. This versatile
antigen coverage could allow these SSXspecific TCRs to be utilized in the
treatment of multiple types of cancer in
a wide array of cancer patients. Infusing
cancer patients with SSX–2 specific T
cells via adoptive immunotherapy could
prove to be a powerful approach for
selectively attacking tumors without
generating toxicity against
noncancerous cells.
Applications
• Immunotherapeutics to treat and/or
prevent the recurrence of a variety of
human cancers, including pancreatic
cancer and melanoma, by adoptively
transferring the gene-modified T cells
into patients whose tumors express a
SSX family member protein recognized
by this TCR.
• A drug component of a combination
immunotherapy regimen aimed at
targeting specific tumor-associated
antigens, including SSX–2, SSX–3,
SSX–4, SSX–5, SSX–9, and/or SSX–10
expressed by cancer cells within
individual patients.
• A research tool to investigate
signaling pathways in SSX–2 expressing
cancer cells.
• An in vitro diagnostic tool to screen
for cells expressing an SSX antigen from
a recognized member of the SSX protein
family.
Advantages
• Selective toxicity for tumor cells—
SSX–2 and other SSX proteins are only
expressed on testis germ cells and tumor
cells. Thus, infused cells expressing an
anti-SSX–2 TCR should target SSXexpressing tumor cells with little or no
toxicity to normal cells. Immunotherapy
with these cells is not anticipated to
elicit harsh side effects to patients.
• Ability to recognize multiple SSX
antigens—Since these SSX–2 directed
TCRs can also recognize five (5)
additional SSX family members (SSX–3,
4, 5, 9, and 10), cells expressing these
TCRs are expected to be able to fight a
larger range of tumor types. If in the
course of attacking SSX–2 expressing
tumor cells in a patient these cells also
encounter tumor cells expressing other
recognized SSX antigens, then these
cells would still be capable of
eliminating the non-SSX–2 expressing
cell. The ability of these TCRs to
recognize multiple SSX antigens may
E:\FR\FM\02DEN1.SGM
02DEN1
Federal Register / Vol. 75, No. 231 / Thursday, December 2, 2010 / Notices
allow it to be utilized to treat a broader
population of patients.
• Versatile antigen recognition—
These TCRs are CD8 and CD4
independent meaning that cells
expressing these TCRs are capable of
eliciting an immune response in the
absence of CD8 or CD4 molecule
expression on the T cell. When utilized
for immunotherapy, this versatility
allows engineered T cells expressing
this TCR to recognize and eliminate
tumors expressing SSX–2 regardless of
how the antigen is presented to the T
cell.
Development Status: This technology
is in a preclinical stage of development.
Inventors: Richard A. Morgan et al.
(NCI).
WReier-Aviles on DSKGBLS3C1PROD with NOTICES
Publications
[FR Doc. 2010–30279 Filed 12–1–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
Federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
SUMMARY:
1. N Chinnasamy, et al. Development
of HLA–A2 Restricted TCR Against
Cancer Testis Antigen SSX–2 for
Adoptive Immunotherapy of Cancer.
Abstracts for the 25th Annual Meeting
of the International Society for
Biological Therapy of Cancer, J
Immunother. 2010 Oct;33(8):860, DOI
10.1097/CJI.0b013e3181f1e08d.
2. D Valmori, et al. Expression of
synovial sarcoma X (SSX) antigens in
epithelial ovarian cancer and
identification of SSX–4 epitopes
recognized by CD4+ T cells. Clin Cancer
Res. 2006 Jan 15;12(2):398–404.
[PubMed: 16428478]
3. G Bricard, et al. Naturally acquired
MAGE–A10- and SSX–2-specific CD8+
T cell responses in patients with
hepatocellular carcinoma. J Immunol.
2005 Feb 1;174(3):1709–1716. [PubMed:
15661935]
Patent Status: U.S. Provisional
Application No. 61/384,931 filed 21
Sept 2010 (HHS Reference No. E–269–
2010/0–US–01).
Related Technologies: T cell receptor
technologies developed against other
CTAs: E–304–2006/0 and E–312–2007/1
(anti-NY–ESO–1) and E–236–2010/0
(anti-MAGE–A3).
Licensing Status: Available for
licensing.
Licensing Contact: Samuel E. Bish,
Ph.D.; 301–435–5282;
bishse@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute, Surgery
Branch, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize the use of T cell receptor
gene therapy for the treatment of cancer.
Please contact John Hewes, Ph.D. at
301–435–3121 or hewesj@mail.nih.gov
for more information.
VerDate Mar<15>2010
Dated: November 24, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
15:28 Dec 01, 2010
Jkt 223001
Mouse Monoclonal Antibody for
CEACAM
Abstract: The following biological
material is a hybridoma cell line
generated from mice lymphocytes
immunized with human mammary
carcinomas and fused to a myeloma cell
line. The resulting mouse monoclonal
antibody (MAb, clone B1.1) is directed
against carcinoembryonic antigen
(CEA). CEA are glyco-proteins whose
expression levels are increased on the
surface of metastatic cancer cells.
Therefore, antibodies generated from the
hybridoma clone B1.1 can be used to
detect cancer cells. MAb B1.1 binds to
the surface of human breast and
melanoma cell lines and cells associated
with colon carcinomas and adenomas.
The antibody has been tested to work
effectively in several techniques such as
Immunofluorescence, Western Blot,
Fluorescent Activated Cell Sorting
PO 00000
Frm 00011
Fmt 4703
Sfmt 4703
75179
(FACS), and Immunohistochemistry
(IHC).
Commercial Applications
• Developing cancer biomarker.
• Developing cell sorting assays (e.g.
FACS).
• Immunofluorescence, Western
Blotting, and Immunohistochemistry for
CEA.
• Developing prognostic assays for
cancer.
Competitive Advantages: Tested to
bind CEA and can be used in different
Immunological Techniques such as
Immunofluorescence, Western Blot,
Fluorescent Activated Cell Sorting
(FACS), and Immunohistochemistry
(IHC).
Materials Available: 1 vial of
Hybridoma cell line (B1.1).
Inventors: Jeffrey Schlom and David
Colcher (NCI).
Related Publications
1. D. Colcher et al. (1983) [PubMed:
6365268].
2. D. Stramignoni et al. (1983)
[PubMed: 6852972].
Patent Status: ‘‘The Generation of
Monoclonal Antibody (MAb) B1.1 and
Its Reactivity to Human Tumors,’’ HHS
Reference No. E–272–2010/0—Research
Material. Patent protection is not being
pursued for this technology.
Licensing Status: Available for
licensing under a Biological Materials
License Agreement.
Licensing Contact: Sabarni Chatterjee,
Ph.D.; 301–435–5587;
chatterjeesa@mail.nih.gov.
Novel Compounds That Specifically
Kill Multi-Drug Resistant Cancer Cells
Description of Technology: One of the
major hindrances to successful cancer
chemotherapy is the development of
multi-drug resistance (MDR) in cancer
cells. MDR is frequently caused by the
increased expression or activity of ABC
transporter proteins in response to the
toxic agents used in chemotherapy. The
increased expression or activity of the
ABC transporter proteins causes the
toxic agents to be removed from cells
before they can act to kill the cell. As
a result, research has generally been
directed to overcoming MDR by
inhibiting the activity of ABC
transporters, thus causing the
chemotherapeutic agents to remain in
the cell long enough to exert their
effects. However, compounds that
inhibit ABC transporter activity often
elicit strong and undesirable side-effects
due to the inhibition of ABC transporter
function in normal cells, thereby
restricting their usefulness as
therapeutics.
E:\FR\FM\02DEN1.SGM
02DEN1
]]>Agencies
[Federal Register Volume 75, Number 231 (Thursday, December 2, 2010)]
[Notices]
[Pages 75177-75179]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-30279]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of Federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Novel Compositions and Methods To Treat Glioblastoma and Other Cancers
Description of Technology: There remains a significant unmet need
for therapeutics to treating glioblastoma multiforme, a very aggressive
type of brain tumor. Glioblastoma is difficult to treat with
conventional surgery, chemical, and radiation therapies. With
approximately 18,000 new glioblastoma cases in the U.S. each year, and
a comparable market in Europe, the global market for such products
forecast to be over $300 million. In light of the high unmet need in
malignant astrocytoma and little in the way of pipeline competition,
this indication represents a potential easy route to market for new
drugs.
[[Page 75178]]
Researchers at the National Cancer Institute (NCI) have identified
two novel molecular targets, annexin 1 (Anx A1) and its receptor formyl
peptide receptor 1 (FPR1), for new anti-glioblastoma therapies. Anx A1
and FPR1 mediate growth, invasion, production of angiogenic factors,
tumor formation, and are abnormally expressed by more highly malignant
glioblastomas. Depletion of Anx A1 in glioblastoma cells resulted in
their reduced capacity to form tumors; additional depletion of FPR1
further reduced this capacity. Further, the NCI researchers have found
a correlation between Anx A1 expression and the degree of malignancy of
human gliomas.
Novel anti-glioblastoma therapies encompassed by this invention
include neutralizing antibodies against Anx A1 and FPR1, small compound
agonists of Anx A1 and FPR1, small interference RNAs (siRNAs) that
deplete Anx A1 and FPR1 from glioblastoma cells, as well as delivery
methods to effectively administer the Anx A1 and FPR1 targeting drugs
into brain tissues.
Applications
Treatment of glioblastoma multiforme and other brain
tumors.
Treatments for inhibiting neoplastic cell growth.
Treatments for inhibiting tumor progression and
metastasis.
Treatments for inhibiting angiogenesis in a tumor.
Advantages
High specificity.
Does not require radiation.
A correlation between expression of the molecular target
and the degree of tumor malignancy is known.
Wide-range/flexibility of potential therapies and
approaches.
Development Status: Pre-clinical.
Inventors: Ji Ming Wang et al. (NCI).
Relevant Publication: Y Zhou, et al. Formylpeptide receptor FPR and
the rapid growth of malignant human gliomas. J Natl Cancer Inst. 2005
Jun 1;97(11):823-835. [PubMed: 15928303]
Patent Status: U.S. Provisional Application No. 61/388,983, filed
01 Oct 2010 (HHS Reference No. E-297-2010/0-US-01).
Licensing Status: Available for licensing.
Licensing Contact: Patrick P. McCue, Ph.D.; 301-435-5560;
mccuepat@mail.nih.gov.
Collaborative Research Opportunity: The Center for Cancer Research,
Laboratory of Molecular Immunoregulation, is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize this
technology. Please contact John Hewes, Ph.D. at 301-435-3121 or
hewesj@mail.nih.gov for more information.
Synovial Sarcoma X Breakpoint-2 (SSX-2) Specific Human T Cell Receptors
for Treating a Wide-Range of Cancers
Description of Technology: Many current approaches for treating
cancer also generate harsh side effects in patients. In addition, a
sizable patient population does not respond to generalized chemotherapy
and radiation treatments for cancer. There is an urgent need to develop
new therapeutic strategies aimed at reducing side-effects and
increasing specific anti-tumor activity in individual patients.
Adoptive immunotherapy is a promising new approach to cancer treatment
that engineers an individual's innate and adaptive immune system to
fight against specific diseases, including cancer. As research and
development continues in this area, scientists continue to improve cell
transfer therapies by targeting an increasing collection of tumor
antigens with more effective immune cell cultures.
T cell receptors (TCRs) are proteins that recognize antigens in the
context of infected or transformed cells and activate T cells to
mediate an immune response and destroy abnormal cells. TCRs consist of
two domains, one variable domain that recognizes the antigen and one
constant region that helps the TCR anchor to the membrane and transmit
recognition signals by interacting with other proteins. When a TCR is
stimulated by an antigen, such as a tumor antigen, some signaling
pathways activated in the cell lead to the production of cytokines,
which mediate the immune response.
Scientists at the National Institutes of Health (NIH) have
developed T cells genetically engineered to recognize synovial sarcoma
X breakpoint-2 (SSX-2) peptide antigens. SSX proteins, including SSX-2,
are expressed primarily by tumor cells from a variety of cancers,
including pancreatic cancer where very few treatment options exist.
Other than germ cells of the testis, normal cells do not express SSX
proteins and, thus, should not be targeted by therapies directed
against these proteins. Therefore, SSX proteins represent a promising
target for cancer immunotherapy. There are ten (10) known members of
the SSX protein family designated SSX-1 through SSX-10. The T cell
receptors (TCRs) developed by these NIH scientists have specificity for
SSX-2 and deliver a robust immune response when they encounter SSX-2
expressing cells. However, these TCRs also recognize five (5) other SSX
family members, including SSX-3, SSX-4, SSX-5, SSX-9, and/or SSX-10,
and deliver a productive, intermediate immune response in the context
of target cells expressing these antigens. This versatile antigen
coverage could allow these SSX-specific TCRs to be utilized in the
treatment of multiple types of cancer in a wide array of cancer
patients. Infusing cancer patients with SSX-2 specific T cells via
adoptive immunotherapy could prove to be a powerful approach for
selectively attacking tumors without generating toxicity against
noncancerous cells.
Applications
Immunotherapeutics to treat and/or prevent the recurrence
of a variety of human cancers, including pancreatic cancer and
melanoma, by adoptively transferring the gene-modified T cells into
patients whose tumors express a SSX family member protein recognized by
this TCR.
A drug component of a combination immunotherapy regimen
aimed at targeting specific tumor-associated antigens, including SSX-2,
SSX-3, SSX-4, SSX-5, SSX-9, and/or SSX-10 expressed by cancer cells
within individual patients.
A research tool to investigate signaling pathways in SSX-2
expressing cancer cells.
An in vitro diagnostic tool to screen for cells expressing
an SSX antigen from a recognized member of the SSX protein family.
Advantages
Selective toxicity for tumor cells--SSX-2 and other SSX
proteins are only expressed on testis germ cells and tumor cells. Thus,
infused cells expressing an anti-SSX-2 TCR should target SSX-expressing
tumor cells with little or no toxicity to normal cells. Immunotherapy
with these cells is not anticipated to elicit harsh side effects to
patients.
Ability to recognize multiple SSX antigens--Since these
SSX-2 directed TCRs can also recognize five (5) additional SSX family
members (SSX-3, 4, 5, 9, and 10), cells expressing these TCRs are
expected to be able to fight a larger range of tumor types. If in the
course of attacking SSX-2 expressing tumor cells in a patient these
cells also encounter tumor cells expressing other recognized SSX
antigens, then these cells would still be capable of eliminating the
non-SSX-2 expressing cell. The ability of these TCRs to recognize
multiple SSX antigens may
[[Page 75179]]
allow it to be utilized to treat a broader population of patients.
Versatile antigen recognition--These TCRs are CD8 and CD4
independent meaning that cells expressing these TCRs are capable of
eliciting an immune response in the absence of CD8 or CD4 molecule
expression on the T cell. When utilized for immunotherapy, this
versatility allows engineered T cells expressing this TCR to recognize
and eliminate tumors expressing SSX-2 regardless of how the antigen is
presented to the T cell.
Development Status: This technology is in a preclinical stage of
development.
Inventors: Richard A. Morgan et al. (NCI).
Publications
1. N Chinnasamy, et al. Development of HLA-A2 Restricted TCR
Against Cancer Testis Antigen SSX-2 for Adoptive Immunotherapy of
Cancer. Abstracts for the 25th Annual Meeting of the International
Society for Biological Therapy of Cancer, J Immunother. 2010
Oct;33(8):860, DOI 10.1097/CJI.0b013e3181f1e08d.
2. D Valmori, et al. Expression of synovial sarcoma X (SSX)
antigens in epithelial ovarian cancer and identification of SSX-4
epitopes recognized by CD4+ T cells. Clin Cancer Res. 2006 Jan
15;12(2):398-404. [PubMed: 16428478]
3. G Bricard, et al. Naturally acquired MAGE-A10- and SSX-2-
specific CD8+ T cell responses in patients with hepatocellular
carcinoma. J Immunol. 2005 Feb 1;174(3):1709-1716. [PubMed: 15661935]
Patent Status: U.S. Provisional Application No. 61/384,931 filed 21
Sept 2010 (HHS Reference No. E-269-2010/0-US-01).
Related Technologies: T cell receptor technologies developed
against other CTAs: E-304-2006/0 and E-312-2007/1 (anti-NY-ESO-1) and
E-236-2010/0 (anti-MAGE-A3).
Licensing Status: Available for licensing.
Licensing Contact: Samuel E. Bish, Ph.D.; 301-435-5282;
bishse@mail.nih.gov.
Collaborative Research Opportunity: The National Cancer Institute,
Surgery Branch, is seeking statements of capability or interest from
parties interested in collaborative research to further develop,
evaluate, or commercialize the use of T cell receptor gene therapy for
the treatment of cancer. Please contact John Hewes, Ph.D. at 301-435-
3121 or hewesj@mail.nih.gov for more information.
Dated: November 24, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2010-30279 Filed 12-1-10; 8:45 am]
BILLING CODE 4140-01-P
